Emyria Ltd

Price Chart

Risk-Adjusted Performance

Emyria Ltd (EMD) Price Performance

Emyria Ltd (EMD) trades on Australian Securities Exchange in AUD. The company is classified in the Healthcare sector under the Health Information Services industry. The stock currently trades at AUD0.06, up 16.67% from the previous close.

Over the past year, EMD has traded between a low of AUD0.02 and a high of AUD0.07. The stock has gained 107.4% over this period. It is currently 24.3% below its 52-week high.

Emyria Ltd has a market capitalization of $37.10M.

About Emyria Ltd

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Leederville, Australia.

Compare Emyria Ltd

Side-by-side comparison against top Healthcare peers.